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Aim To identify the factors associated with vitamin D status 
in patients with chronic graft-vs-host disease (cGVHD) and 
evaluate the association between serum vitamin D (25(OH)
D) levels and cGVHD characteristics and clinical outcomes 
defined by the National Institutes of Health (NIH) criteria.
Methods 310 cGVHD patients enrolled in the NIH cGVHD 
natural history study (clinicaltrials.gov: NCT00092235) 
were analyzed. Univariate analysis and multiple logistic 
regression were used to determine the associations be-
tween various parameters and 25(OH)D levels, dichoto-
mized into categorical variables: ≤20 and >20 ng/mL, and 
as a continuous parameter. Multiple logistic regression was 
used to develop a predictive model for low vitamin D. Sur-
vival analysis and association between cGVHD outcomes 
and 25(OH)D as a continuous as well as categorical vari-
able: ≤20 and >20 ng/mL; <50 and ≥50 ng/mL, and among 
three ordered categories: ≤20, 20-50, and ≥50 ng/mL, was 
performed.
Results 69 patients (22.3%) had serum 25(OH)D ≤20 ng/
mL. Univariate analysis showed that supplement intake, 
nutritional status (severely malnourished, moderately mal-
nourished, well-nourished), race (African-American, other), 
and estimated creatinine clearance (eCCr) were associated 
with 25(OH)D levels. A predictive model was developed 
based on supplement intake, nutritional status, race, and 
eCCr, accurately predicting 77.9% of patients with 25(OH)
D ≤20 and 65.2% of those with 25(OH)D >20 ng/mL. No as-
sociation was found between vitamin D and major cGVHD 
characteristics, but patients with 25(OH)D ≤20 ng/mL had 
somewhat decreased survival.
Conclusion Nutritional status and adequate supplemen-
tation are important to maintain 25(OH)D >20 ng/mL in 
cGVHD patients. Intervention studies and more research is 
needed to reveal the underlying mechanism of vitamin D 
metabolism in cGVHD setting.
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Humans get vitamin D in two major forms: cholecalciferol, 
which can be obtained when the skin is exposed to so-
lar UV-B radiation and from a few animal-based foods, and 
ergocalciferol, which is obtained from dietary sources (1). 
Both forms are found in vitamin D supplements and for-
tified foods. Vitamin D from the skin and diet is metabo-
lized in the liver to 25-hydroxivitamin D (calcidiol) [25(OH)
D], which is considered to be the most useful marker of 
vitamin D status, which incorporates endogenous synthe-
sis from solar exposure, dietary intake from foods, fortified 
products, and supplements (2). 25(OH)D is further convert-
ed via the action of 1-α-hydroxylase primarily in the kidney 
to 1,25-dihydroxyvitamin D (calcitriol) [1,25(OH)2D], the 
physiologically active form of vitamin D (1).
Targeting various immune cells, including monocytes, 
macrophages, dendritic cells, and T- and B-lymphocytes, 
vitamin D has a significant role in the maintenance of im-
mune homeostasis (3), and its deficiency has been associ-
ated with a higher susceptibility to autoimmune diseases 
(4). Since chronic graft-vs-host disease (cGVHD) is a multi-
organ alloimmune and autoimmune disorder that occurs 
following allogeneic hematopoietic stem cell transplan-
tation (allo-HSCT), characterized by immune dysregula-
tion, immunodeficiency, impaired organ function, and de-
creased survival (5), vitamin D deficiency may represent a 
factor of influence for various cGVHD outcomes. Recent 
studies have shown that low vitamin D level before allo-
HSCT is an independent risk factor for the development 
of cGVHD (6,7). Also, Silva et al (8) found that the sever-
ity of cGVHD assessed according to National Institutes of 
Health (NIH) response criteria (9) improved in a small group 
of cGVHD patients who received vitamin D supplementa-
tion for osteoporosis or osteopenia. The 2014 NIH cGVHD 
Consensus Project Ancillary and Supportive Care guide-
lines prescribe yearly monitoring of serum 25(OH)D within 
the recommendations for prevention and management of 
osteoporosis (10).
Still, there is a lack of knowledge on the role of vitamin D 
in modulating immunological functions in the cGVHD set-
ting, especially in patients with long-standing moderate 
or severe cGVHD who have failed many lines of therapy. 
Patients with cGVHD represent a unique population with 
complex and multiple factors influencing vitamin D lev-
els. The risk of vitamin D inadequacy in cGVHD is increased 
since patients are routinely instructed to minimize sun ex-
posure to avoid the exacerbation of cutaneous GVHD (10). 
Furthermore, glucocorticoid therapy, reduced skin synthe-
sis, lower dietary intake, malabsorption, and/or inadequate 
hepatic and renal hydroxylation to vitamin D active me-
tabolites are additional risks for insufficient levels of vita-
min D (1). This study was undertaken to identify the factors 
associated with vitamin D status, and determine its poten-
tial association with cGVHD disease outcomes defined by 
the NIH criteria.
PaTIenTS anD MeThoDS
This cross-sectional study included patients enrolled in 
an ongoing National Institutes of Health protocol, Pro-
spective Assessment of Clinical and Biological Factors 
Determining Outcomes in Patients with Graft-vs-Host 
Disease (clinicaltrials.gov identifier: NCT00092235) be-
tween October 2004 and May 2015. All patients signed 
National Cancer Institute Institutional Review Board-
approved consent and reported for a 1-week compre-
hensive multidisciplinary evaluation, which included 
subspecialist examinations in dentistry, dermatology, gy-
necology, ophthalmology, pain and palliative care, reha-
bilitation medicine, and hematology/oncology. Disease 
assessment was done using the NIH cGVHD diagnostic 
and staging system (11). Additionally, patients under-
went nutritional evaluation by a certified nutritionist, us-
ing Patient-Generated Subjective Global Assessment (PG-
SGA) malnutrition screening tool recommended by the 
American Society of Parenteral and Enteral Nutrition in 
cancer patients (12). For each individual, a total PG-SGA 
score was calculated and a PG-SGA global rating was es-
tablished (well-nourished, moderately or suspected of 
being malnourished, or severely malnourished) (13). Fur-
thermore, self-reported, recent (over the past month) or 
current supplement use was recorded (none, vitamin 
D, multivitamin, both). Blood was drawn for chemistry 
panels, complete blood counts, and other routine labo-
ratory tests, including serum 25(OH)D. Serum 25(OH)D 
was measured by liquid chromatography-tandem mass 
spectrometry from October 2004 to January 2014 (Mayo 
Clinic Laboratories, Rochester, MN, USA, 2004-2010, and 
Department of Laboratory Medicine, Clinical Center, NIH, 
USA, January 2011-2014), and chemiluminescence im-
munoassay (DiaSorin, Stillwater, MN, USA) effective Janu-
ary 29, 2014 (Department of Laboratory Medicine, Clinical 
Center, NIH, USA). Vitamin D deficiency was defined as se-
rum 25(OH)D concentration ≤20 ng/mL (1).
Potential factors influencing vitamin D level in our patient 
population included several sets of variables: age, sex, 
race (self-reported: African-American vs other), body 
mass index (BMI), blood drawing season classified 
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in an ordered fashion: winter (December through Febru-
ary), spring and fall (March through May and September 
through November), and summer (June through August), 
supplement intake, and physical activity. Supplement in-
take association with 25(OH) level was assessed in several 
categories: none vs vitamin D and/or multivitamin intake 
(any); none or only multivitamin intake vs vitamin D or vi-
tamin D and multivitamin intake; and none or multivita-
min only or vitamin D only vs both vitamin D and multivi-
tamin intake. Physical activity was assessed using scores of 
PG-SGA activities and function evaluation (mostly inactive 
vs fairly normal activity) (13) as well as the Human Activ-
ity Profile (maximal activity score HAP MAS, and adjusted 
activity score HAP AAS) patient-reported questionnaire of 
energy expenditure or physical fitness (14).
We also considered transplant characteristics including to-
tal body irradiation (yes vs no), intensity of conditioning 
(myeloablative vs non-myeloablative/reduced intensity 
conditioning), HLA match (match vs mismatch), donor re-
lationship (related vs unrelated), indication for allo-HSCT, 
stem cell source (bone marrow, peripheral blood, or cord 
blood), and time since transplant.
Finally, we considered a number of variables that reflect-
ed cGVHD activity and severity including time since di-
agnosis of cGVHD, history of acute GVHD, body surface 
area of deep and dermal sclerotic skin involvement (de-
fined as percentage of total body surface area), serum 
markers of inflammation (platelet count, C3 and C4 com-
plement components, C-reactive protein [CRP], and al-
bumin), number of prior systemic immunosuppressive 
therapies, intensity of current immunosuppression (de-
fined per Mitchell et al (15) as none, mild = single-agent 
prednisone <0.5 mg/kg/d, moderate = prednisone ≥0.5 
mg/kg/d and/or any single agent/modality, and high = 2 
or more agents/modalities ± prednisone ≥0.5 mg/kg/d), 
and current glucocorticoid dose converted to equivalent 
prednisone dose. Renal function was assessed by estima-
tion of creatinine clearance (eCCr) using the Cockroft-
Gault equation (16).
Chronic GVHD outcomes assessed for association with vi-
tamin D included NIH global score (11), average NIH or-
gan score (sum of all NIH organ scores divided by number 
of organs assessed; 7 for men, 8 for women), NIH Lung 
Score (11), number of organs affected, cGVHD activity 
(defined by clinician impression: inactive vs active and 
highly active), GVHD Physician Global Symptom Se-
verity Score (9), and Lee Symptom Scale Total Score 
(17). Follow-up for survival analysis was carried out begin-
ning with the date of entry onto the protocol until death 
or last follow up.
Statistical analysis
Univariate associations between a set of parameters and 
continuous or categorized vitamin D level (≤20 vs >20 ng/
mL) were initially determined prior to performing multi-
variable analyses. Statistical methods used in these uni-
variate analyses included the following: exact Wilcoxon 
rank sum test, Kruskal-Wallis test, Fisher exact test, Mehta’s 
modification to Fisher exact test (18), Jonckheere-Terp-
stra trend test (19), Cochran-Armitage trend test (20), and 
Spearman rank correlation. Spearman correlations were 
interpreted as follows: r >0.70 = strong correlation; 0.5<r 
<0.7 = moderately strong correlation; 0.3<r <0.5 = weak to 
moderately strong correlation; r <0.3 = weak correlation. 
In view of the large number of exploratory analyses per-
formed to determine factors associated with vitamin D or 
vitamin D≤20 ng/mL, only P < 0.005 was considered statis-
tically significant. Following the initial univariate screening 
analyses, multiple logistic regression analyses were used 
to determine the association between parameters and 
categorized vitamin D. Analyses to determine the associa-
tion between continuous vitamin D level, as well as cat-
egorized vitamin D level (≤20 vs >20 ng/mL; <50 vs ≥50 
ng/mL; and ≤20 vs 20-50 vs ≥50 ng/mL as ordered cate-
gories) and a variety of cGVHD outcomes were performed. 
Kaplan-Meier analyses and log-rank tests were used to de-
termine the association between potential predictors and 
survival after entering on the trial. Beginning with univari-
ate parameters with P < 0.050 in the initial screening for 
association with vitamin D level, multiple logistic regres-
sion was used to develop a predictive model for low vi-
tamin D. All P-values are two tailed and reported without 
any adjustment for multiple comparisons. Analyses were 




Initial screening was performed on 364 patients; 17 pa-
tients who were not diagnosed with cGVHD at evalua-
tion or who failed to complete the study, 29 pediatric pa-
tients, and 8 patients who lacked 25(OH)D measurement 
were excluded. The final sample consisted of 310 adult 
participants.
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The median age was 48 years (interquartile range [IQR], 
36-57) and 172 participants were men (55%). The most fre-
quent indications for transplant were acute leukemia and 
myelodysplastic syndrome (47%), followed by lymphoma 
(24%). Myeloablative conditioning was more common 
(55%) than reduced intensity conditioning (45%). Patients 
predominantly received peripheral blood stem cells (82%), 
usually from HLA-matched donors (84%), and 188 patients 
(61%) were related to their respective donors (Table 1).
Patients were diagnosed with cGVHD a median of 223 days 
(IQR, 145-373) after transplant and were enrolled a medi-
an of 1105.5 (IQR, 692-1819) days after transplant. Most 
patients had severe (72%), followed by moderate (26%), 
cGVHD assessed by NIH global scoring. The median aver-
age NIH organ score was 1.13 (IQR, 0.75-1.43) with a me-
dian of 5 affected organs (IQR, 4-6). Patients were most 
frequently on high (39%) or moderate (37%) intensity im-
munosuppression and had failed a median of 4 prior sys-
temic therapies (IQR, 2-5; Table 2).
Serum 25(oh)D levels and determination of associated 
factors
The median value of serum 25(OH)D for all 310 patients 
was 30 ng/mL (IQR 22-42). 241 patients (77.7%) had se-
rum 25(OH)D>20 ng/mL and 69 (22.3%) had 25(OH)D≤20 
ng/mL.
Significantly more patients with 25(OH)D>20 ng/mL used 
a vitamin D supplement or a multivitamin compared to 
those who used no supplementation (P < 0.001). Also sig-
nificantly more patients with 25(OH)D≤20 ng/mL used no 
supplementation or used multivitamin only compared to 
TabLe 1. Demographic characteristics of patients with with chronic graft-vs-host disease
n (% or interquartile range)
all 310





acute lymphocytic leukemia, acute myeloid leukemia, myelodysplastic syndrome 146 (47)
chronic myeloid leukemia, idiopathic myelofibrosis, myeloproliferative disorder  40 (13)
chronic lymphocytic leukemia  22 (7)
Hodgkin’s lymphoma, non-Hodgkin’s lymphoma  74 (24)
multiple myeloma  15 (5)
aplastic anemia, paroxysmal nocturnal hemoglobinuria   7 (2)




unknown   2 (<1)
Stem cell source
bone marrow  53 (17)
peripheral blood stem cells 253 (82)




unknown   2 (<1)
human leukocyte antigen match
yes 260 (84)
no  43 (14)
unknown   7 (2)
*other includes ewing’s sarcoma, essential thrombocythemia, Kostmann syndrome sickle cell anemia, and Wiskott-aldrich syndrome.
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patients who were taking vitamin D or both (vitamin D and 
multivitamin) (P < 0.001,Table 3).
Overall, 175 (56%) patients reported recent or current sup-
plement use, and they had significantly higher 25(OH)D 
levels than non-users; P < 0.001). Patients who reported 
vitamin D or vitamin D and multivitamin intake had sig-
nificantly higher 25(OH)D levels than patients who were 
taking no supplements or multivitamin only (P < 0.001). Pa-
tients who reported taking both supplements (vitamin D 
and multivitamin) had significantly higher 25(OH)D levels 
than patients who were taking no supplements or multivi-
tamin only or vitamin D only (P < 0.001; Table 4).
There was a significant positive association between PG-
SGA nutritional evaluation, categorized in an increasing 
ordered fashion as severely malnourished compared to 
suspected or moderately malnourished compared to well-
nourished group, and greater serum 25(OH)D in two cat-
egories, ≤20 and >20 ng/mL; P = 0.004). When nutrition-
al status was dichotomized to the malnourished group, 
which included both severely malnourished and suspect-
TabLe 2. Chronic graft-vs-host disease (cGVhD) characteristics
n (% or interquartile range)
all  310
Median days from transplant to cGVhD diagnosis  223 (145-373)
Median days from cGVhD diagnosis to consent  737 (338-1465)
Median days from transplant to consent 1105.5 (692-1819)
cGVhD organ involvement*
skin  243 (78)
joints and fascia  193 (62)
eyes  250 (81)
mouth  212 (68) 
lungs  237 (76)
liver  157 (51)
gastrointestinal tract  139 (45)
genital (females only, N = 138)   80 (58)
average National Institutes of Health (NIH) organ score    1.13 (0.75-1.43)
number of organs affected by cGVhD median 5 (4-6)
1-2 affected organs   14 (5)
3-4 affected organs  110 (35)
5-6 affected organs  133 (43)
7-8 affected organs   53 (17)
nIh Global Score†
mild    5 (2)
moderate   81 (26)
severe  224 (72)
Prior cGVhD systemic treatment regimens
<2   31 (10)
2-3  106 (34)
4-5  113 (36)
>5   59 (19)
unknown    1 (<1)
Intensity of current immunosuppression‡
none/mild   74 (24)
moderate  115 (37)
high  121 (39)
*cGVhD organ involvement per nIh organ staging (11).
†Definition for nIh Global score is as follows: mild (1 to 2 organs affected by chronic GVhD with scores of 1), moderate (more than 2 organs with 
score of 1, any score of 2, or lung score of 1), or severe (any score of 3 or lung score of 2) (11).
‡Definition of intensity of current immunosuppression is as follows: mild (single-agent prednisone 0.5 mg/kg/d), moderate (single-agent prednisone 
0.5 mg/kg/d and/or any single agent/modality), high (2 or more agents/modalities +/− prednisone 0.5 mg/kg/d) (15).
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TabLe 3. Qualitative parameters and their association with categorized 25(oh)D level
25(oh)D≤20 ng/mL n (%) 25(oh)D>20 ng/mL n (%) P
Race
African-American 7 (53.8) 6 (46.2)  0.011*
non-African-American 62 (20.9) 234 (79.1)
Vitamin D supplementation
none 46 (34.6) 87 (65.4) <0.001*
vitamin D and/or multivitamin 23 (13.1) 152 (86.9)
none or multivitamin 58 (28.7) 144 (71.3) <0.001*
vitamin D or vitamin D and multivitamin 11 (10.4) 95 (89.6)
none or multivitamin or vitamin D 66 (24.9) 199 (75.1)  0.009*
vitamin D and multivitamin 3 (7.0) 40 (93.0)
Patient-Generated Subjective Global assessment
severely malnourished 10 (55.6) 8 (44.4)  0.004†
moderately malnourished 20 (23.8) 64 (76.2)
well-nourished 38 (19.4) 158 (80.9)
moderately/severely malnourished 30 (29.4) 72 (70.6)  0.059*
well-nourished 38 (19.4) 158 (80.6)
*Fisher exact test.
†Cochran-armitage trend test.





male 28 (21-36.5)  0.009*
female 31.5 (24-45)  
Race
African-American 18 (14-35)  0.093*
non-African-American 30 (23-42)
Vitamin D supplementation
none 25 (17-32) <0.001*
vitamin D and/or multivitamin 34 (26-45)
none or multivitamin 26 (20-36) <0.001*
vitamin D or vitamin D and multivitamin 34.5 (27-48)
none or multivitamin or vitamin D 28 (21-39) <0.001*
vitamin D and multivitamin 39 (30-52)
Patient-Generated Subjective Global assessment Physical activity and Function
inactive 27.5 (19-39)  0.055*
active 31 (23-43)
Disease
acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndrome 31 (23-44)  0.099†
chronic myeloid leukemia 25 (23-34)
chronic lymphocytic leukemia 24 (16-35)
lymphoma 33 (24-43)
other§ 29.5 (22-32)
acute leukemia, myelodysplastic syndrome, or lymphoma 31 (23-43)  0.009*
chronic myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, and other§ 26 (20.5-33.5)
*Wilcoxon rank sum test.
†Kruskal-Wallis test with Monte Carlo estimate for an exact test.
§other include sarcoma, immunodeficiency, aplastic anemia, paroxysmal nocturnal hemoglobinuria, ewing’s sarcoma, essential thrombocythemia, 
sickle cell anemia, and Wiskott-aldrich syndrome.
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ed or moderately malnourished categories, and well-nour-
ished group, the significance of the association between 
nutritional status with serum 25(OH)D was lost (P = 0.059). 
Also, no significant association between serum 25(OH)
D and PG-SGA score was found. Serum 25(OH)D≤20 ng/
mL was somewhat more frequent in African American 
than in non-African American patients (P = 0.011, Table 3), 
with lower actual 25(OH)D in African Americans compared 
to non-African Americans but not significantly (P = 0.093, 
Table 4). Serum 25(OH)D was somewhat lower in men 
than women, but the difference was also not significant 
(P = 0.009). Patients who reported being mostly inactive in 
PG-SGA activities and function section did not have sig-
nificantly lower 25(OH)D than patients who reported nor-
mal and fairly normal activity (P = 0.055). With respect to 
its association with the primary disease, somewhat high-
er serum 25(OH)D level was associated with having either 
acute lymphocytic leukemia (ALL), acute myeloid leuke-
mia (AML), myelodysplastic syndrome, Hodgkin’s lympho-
ma, and non-Hodgkin’s lymphoma rather than with having 
chronic myeloid leukemia, chronic lymphocytic leukemia, 
multiple myeloma, or other diseases with, but the differ-
ence was not significant (P = 0.009; Table 4).
The association between BMI, age, and blood drawing sea-
son and serum 25(OH)D in low, ≤20 ng/mL group was not 
significant (P = 0.869, 0.195, and 0.844, respectively). No 
significant correlations were found between serum 25(OH)
D and laboratory blood values (serum creatinine, alkaline 
phosphatase, ALT, AST, GGT, platelet count, CRP, albumin, 
and magnesium).
Serum 25(OH)D was weakly negatively correlated with 
eCCr (r = -0.22, P < 0.001) and somewhat higher eCCr was 
found in patients with 25(OH)D≤20 ng/mL (median 104.3, 
IQR 80.5-135.8) than in patients with >20 ng/mL (median 
of 93.1, IQR 69.0-123.8) (P = 0.012). A weak positive corre-
lation was found between 25(OH)D and time from trans-
plant (r = 0.17, P = 0.002).
Prednisone dose was not correlated with serum 25(OH)D 
(r = 0.047, P = 0.414) and it did not significantly differ be-
tween 25(OH)D≤20 ng/mL (median 0.13, IQR 0-0.36) and 
>20 ng/mL patients (median 0.10, IQR 0-0.32) (P = 0.920). 
No correlation was found between 25(OH)D and dermal 
sclerosis, deep sclerosis, or erythema. There was no signifi-
cant difference with respect to 25(OH)D≤20 or >20 in TBI 
conditioning, myeloablative conditioning, HLA match, do-
nor relationship, bone marrow, peripheral blood or cord 
blood cell source, intensity of immunosupression, pri-
or diagnosis of acute GVHD, acute skin, GI or liver GVHD, 
cGVHD classification at evaluation, or cGVHD onset (data 
not shown).
Multivariable logistic model for the prediction of serum 
25(oh)D status
Based on univariate analyses with P < 0.05, eCCr, race (Af-
rican American vs other), supplement intake (vitamin D 
and/or multivitamin), and PG-SGA global assessment 
(malnourished, suspected or moderately malnourished, 
and well nourished) were included in a multiple logistic 
regression model to predict vitamin D status. By back-
ward elimination, a predictive model was developed (Ta-
ble 5). This model accurately predicted 77.9% (53/68) of 
patients with vitamin D≤20 ng/mL and 65.2% (148/227) 
of patients with vitamin D>20 ng/mL. This is an improve-
ment over the single most predictive univariate factor 
TabLe 5. Predictive model for vitamin D status in chronic graft-vs-host disease*
Variables P Classification rule 25(oh)D≤20 ng/mL 25(oh)D>20 ng/mL
Creatinine clearance† (value) 0.001 X = (-0.0101 x Crea-
tinine Clearance) 
+ (1.0376 × Race) + 
(1.1915 × Vitamin D 
Supplementation) - 








Vitamin D supplementation <0.001
none (0)
vitamin D and/or multivitamin (1)
Patient-Generated Subjective Global Assessment 0.005 If X≤1.3431, predicts 
25(OH)D≤20 ng/mLseverely malnourished (2)
moderately malnourished (1) If X>1.3431, predicts 
25(OH)D>20 ng/mLwell-nourished (0)
*Multiple logistic regression modeling was used to generate models predictive for vitamin D level. Created by backward elimination the resulting 
model was converted into a classification rule that determines the following relationship.
†Creatinine clearance estimated using Cockroft-Gault equation (16).
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that was identified as the use of vitamin D and/or multi-
vitamin supplements.
Serum 25(oh)D level association with cGVhD outcomes 
and survival
No significant association was found between continuous 
vitamin D level or, categorized vitamin D level as ≤20 com-
pared to >20 ng/mL; <50 compared to ≥50 ng/mL; and 
≤20 compared to 20-50 or ≥50 ng/mL as ordered catego-
ries, with major cGVHD outcomes including NIH global se-
verity score, NIH average score, number of organs affected 
by cGVHD, NIH Lung Score, cGVHD activity (active vs inac-
tive), GVHD Physician Global Symptom Severity Score, and 
Lee Symptom Scale Total Score (data not shown).
Patients with vitamin D≤20 ng/mL had somewhat de-
creased overall survival than those with 25(OH)D>20 ng/
mL, but the difference was not significant (P = 0.042, Figure 
1). As a further descriptive evaluation, patients were further 
divided into the following groups: 25(OH)D≤20 vs 20-50 
vs ≥50 ng/mL and their survivals were compared together 
(Figure 2; global P = 0.100). Patients with 25(OH)D≤20 ng/
mL had somewhat, but not significantly, worse overall sur-
vival than patients with 25(OH)D≥50 ng/mL (P = 0.040), but 
there was no difference in survival between 25(OH)D = 20-
50 and 25(OH)D≥50 ng/mL groups (P = 0.970).
DISCuSSIon
This study comprising a large group of cGVHD patients 
showed a significant difference between patients with 
25(OH)D level ≤20 and >20 ng/mL in the use of supple-
ments (none, vitamin D and/or multivitamin), and PG-SGA 
global rating for nutritional status (P < 0.005). Also, the uni-
variate screening analyses between patients with 25(OH)D 
level ≤20 and >20 ng/mL showed an association with race 
(African-American compared to others) as well as eCCr 
(P < 0.05). The logistic regression model, based on supple-
ment use, race, eCCr and nutritional status, correctly clas-
sified 77.9% of participants to have 25(OH)D≤20 ng/mL. 
This is the first model to our knowledge for predicting the 
likelihood of vitamin D deficiency in cGVHD patients. The 
single most predictive factor of vitamin D status was the 
use of vitamin D and/or multivitamin supplements. This 
supports the findings of a study where 65% of long-term 
HSCT survivors had serum 25(OH)D concentrations above 
30 ng/mL at least 1 year after HSCT, while 58% of all par-
ticipants reported regular use of vitamin D supplements 
(21). Regular or occasional use of supplements could also 
explain our observation of a weak positive correlation be-
tween 25(OH)D with the time from transplant. Associa-
tion between low vitamin D and more recent allo-HSCT 
FIGuRe 1. Survival analysis for vitamin D in chronic graft-vs-host disease (cGVhD). 
Patients with serum 25(oh)D≤20 ng/mL had somewhat poorer survival than 
patients with serum 25(oh)D>20 ng/mL (P = 0.042).
FIGuRe 2. Survival analysis for vitamin D in groups of chronic graft-vs-host disease 
(cGVhD) patients stratified by serum level of 25(oh)D≤20 vs 20-50 vs ≥50 ng/mL. 
Patients with 25(oh)D≤20 ng/mL had somewhat poorer survival than patients with 
25(oh)D≥50 ng/mL (P = 0.040), but no difference in survival was found between 
groups with serum 25(oh)D in a range of 20-50 ng/mL and those with ≥50 ng/mL
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was also reported in patients with AML and ALL, most of 
whom had GVHD (22).
In our study, African-American race was associated with 
low vitamin D level, similar to studies in the general popu-
lation, which showed that African Americans were at high 
risk for vitamin D insufficiency and all-cause mortality at 
lower 25(OH)D concentrations than whites (23,24).
In the general population, higher BMI is associated with vi-
tamin D deficiency (25). In our study, higher BMI was not 
significantly associated with lower vitamin D, contrary to 
studies in long-term adult survivors of HSCT (21), patients 
undergoing HSCT (26), or cancer patients (27-29). Further-
more, we did not find an association between 25(OH)D 
and serum albumin, a routine marker of undernutrition. 
However, we found an association between serum 25(OH)
D levels ≤20 ng/mL and severe and moderate malnutri-
tion assessment per global PG-SGA rating. A recent study 
on malnutrition in patients with cGVHD observed a mis-
match between BMI and nutritional evaluation per global 
PG-SGA rating, showing that BMI is not a reliable measure 
of nutritional status in cGVHD setting (30). Taken together, 
our findings support the use of PG-SGA global assessment 
for nutritional evaluation of cGVHD patients in detecting 
severely and moderately malnourished patients who are 
at a greater risk of vitamin D deficiency.
We observed a previously not reported higher eCCr in 
patients with 25(OH)D≤20 and negative correlation be-
tween eCCr and serum 25(OH)D. It has been reported 
that corticosteroids and vitamin D metabolites probably 
modify the production rate and the release of creatinine, 
although treatment with calcitriol does not appear to 
change glomerular filtration rate (GFR) (inulin clearance) 
(31). A study on nondialyzed patients with chronic renal 
failure found that eCCr positively correlated with serum 
levels of 1,25(OH)2D. No correlation was observed with 
25(OH)D, but the levels of [24,25(OH)2D] were significant-
ly associated with 25(OH)D, presumably largely via the ac-
tivation of extrarenal 25(OH)D 24-hydroxylase (32), which 
represents the catabolic pathway of vitamin D where both 
1,25(OH)2D and 25(OH)D are metabolized to the water-
soluble biologically inactive calcitroic acid (33). It has been 
shown that glucocorticoids affect vitamin D metabolism 
by activating the conversion of 25(OH)D and 1,25(OH)2D 
to calcitroic acid (33), and also that acute and chronic ad-
ministrations of glucocorticoids increase GFR (34). Con-
trary to expected, our results did not show an associa-
tion between serum 25(OH)D with prednisone dose, 
although the majority of patients were on high (39%) and 
moderate (37%) intensity immunosuppression. In contrast 
to our results, Robien et al (21) found prednisone level to 
be significantly inversely associated with serum 25(OH)D 
in long-term survivors of HSCT. 80% of their participants 
unlike in our study, were not on prednisone therapy at the 
time, and less than half had a history of acute or chronic 
GVHD. We speculate that severe cGVHD patients on long-
term immunosuppression, which could be associated 
with increased eCCr, may have impaired vitamin D me-
tabolism in terms of increased vitamin D catabolism and 
conversion to its inactive form.
Although serum 25(OH)D levels may function as a vita-
min D biomarker of exposure, it is not clearly established 
which 25(OH)D levels serve as a biomarker of effect (2). 
When we used a cut-off value of 20 ng/mL, there were no 
significant differences with any of the major cGVHD out-
comes and these two levels of vitamin D. Currently, some 
authors claim that the preferred range of serum 25(OH)D 
is 40-60 ng/mL (35). However, our study found no signifi-
cant differences in major cGVHD clinical outcomes criteria 
between groups with serum 25(OH)D<50 and ≥50 ng/mL 
as well as among groups with serum 25(OH)D≤20 vs 20-
50 vs ≥50 ng/mL.
Due to the fact that this was a cross-sectional study with 
a longitudinal survival follow-up, we were not able to ob-
serve the change in cGVHD activity and severity pre and 
post vitamin D supplementation. Also, limitations of this 
study include the absence of a control group of patients 
after allo-HSCT without cGVHD. However, patients with 
vitamin D≤20 ng/mL had somewhat decreased overall 
survival (P = 0.042). A recent study by Wallace et al (36) in 
children showed an association between vitamin D<20 
ng/mL at 100 days post-HSCT and decreased overall sur-
vival, with no difference in survival between children with 
vitamin D levels above and below 30 ng/mL at day 100. 
Another recent study HSCT found significant association 
between serum 25(OH)D<10 ng/mL with overall survival 
when adjusted for age ≥40 (7). Our observations at differ-
ent cutoff points suggest that serum 25(OH)D≤20 ng/mL 
may be associated with decreased survival in cGVHD pa-
tients. Finally, this study was prone to referral center bias. 
The NIH/NCI natural history of cGVHD study primarily en-
rolled patients who had failed several lines of therapy and 
sought expert opinion and additional options. However, 
these are patients with the greatest burden of the disease 
and associated disability who may most benefit from time-
ly preventive and intervention strategies.
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Although increasing evidence supports the role of vita-
min D in modulating the immune system, in the context 
of cGVHD setting many details still remain unknown. Inter-
vention studies are needed to evaluate the best strategies 
of timely and adequate vitamin D supplementation in the 
setting of allo-HSCT and cGVHD, as well as to reveal under-
lying mechanisms of vitamin D metabolism in the complex 
cGVHD setting.
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